tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLLS Stock Latest News

Cellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
Company AnnouncementsCellectis Sets 2026 Clinical Milestones and Extends Cash Runway Into H2 2027
11d ago
6K
CLLS
Cellectis initiated with a Buy at Clear Street
PremiumThe Fly
Cellectis initiated with a Buy at Clear Street
28d ago
CLLS
Cellectis Announces Arbitral Decision in Servier Dispute
PremiumCompany Announcements
Cellectis Announces Arbitral Decision in Servier Dispute
1M ago
6K
CLLS
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
PremiumThe Fly
Allogene Therapeutics says favorable result for Servier in Cellectis arbitration
1M ago
ALLO
CLLS
Cellectis announces arbitral decision in dispute with Servier
PremiumThe Fly
Cellectis announces arbitral decision in dispute with Servier
1M ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
PremiumCompany AnnouncementsCellectis Unveils Promising Phase 1 Results for Eti-cel at ASH 2025
1M ago
6K
CLLS
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
Premium
Company Announcements
Cellectis S.A. Updates Patent License Agreement with University of Minnesota
2M ago
6K
CLLS
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
Premium
Company Announcements
Cellectis Unveils Breakthrough in Non-Viral Gene Editing with CssDNA
2M ago
6K
CLLS
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
PremiumRatings
Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones
2M ago
CLLS
Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
PremiumCompany Announcements
Cellectis S.A. Releases Interim Financial Report for Nine-Month Period Ending September 2025
2M ago
6K
CLLS
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
PremiumThe Fly
Cellectis reports Q3 adjusted EPS 2c vs (22c) last year
2M ago
CLLS
CLLS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CLLS Earnings this Week: How Will it Perform?
3M ago
CLLS
Cellectis Showcases Promising Clinical Trial Data at ASH 2025
PremiumCompany AnnouncementsCellectis Showcases Promising Clinical Trial Data at ASH 2025
3M ago
6K
CLLS
Cellectis to present development update for eti-cel at ASH 2025
Premium
The Fly
Cellectis to present development update for eti-cel at ASH 2025
3M ago
CLLS
Cellectis to Announce Q3 2025 Financial Results on November 7
Premium
Company Announcements
Cellectis to Announce Q3 2025 Financial Results on November 7
3M ago
6K
CLLS
Cellectis price target raised to $4 from $3 at Wells Fargo
PremiumThe Fly
Cellectis price target raised to $4 from $3 at Wells Fargo
3M ago
CLLS
Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
PremiumCompany Announcements
Cellectis Unveils Promising Phase 1 Results for Lasme-cel in r/r B-ALL
3M ago
6K
CLLS
Cellectis price target raised to $8 from $4 at Barclays
PremiumThe Fly
Cellectis price target raised to $8 from $4 at Barclays
3M ago
CLLS
Cellectis Showcases Pipeline Progress at R&D Day
PremiumCompany Announcements
Cellectis Showcases Pipeline Progress at R&D Day
3M ago
6K
CLLS
Cellectis Unveils Promising Gene Therapy Advances at ESGCT Congress
PremiumCompany AnnouncementsCellectis Unveils Promising Gene Therapy Advances at ESGCT Congress
3M ago
6K
CLLS
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
Premium
Ratings
Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations
5M ago
CLLS
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
Premium
Company Announcements
Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment
6M ago
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >